AbCellera Shares Jump 34% After ABCL635 Passes Phase 2 Trial

Shares of AbCellera Biologics Inc. jumped 34% on Monday following positive Phase 2 results for its investigational menopause treatment, which achieved both primary efficacy measures. The results position ABCL635 as the most significant asset in AbCellera’s internal pipeline.

Biotechnology · NASDAQ:ABCL · Pharmaceuticals · Stock Market
Follow on Google News
Add as preferred source Open in Google News

US Stock Market Today Updates

AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 Strong Buy

NVIDIA

94/100
#2 Strong Buy

Meta Platforms

89/100
#3 Buy

Alphabet

87/100
#4 Buy

Amazon

84/100
#5 Selective Buy

Microsoft

80/100
View full portfolio
Editorial model selection. Not personalised advice.
MARKET CALENDAR

Key Events Today

The catalysts most likely to move markets.

#1

Warsh at Jackson Hole

Policy tone can move rates, USD, equities, gold and crypto simultaneously.

#2

Michigan sentiment

A weak final reading or elevated inflation expectations could pressure risk assets.

#3

Chicago PMI

A surprise versus 58.0 may alter the near-term manufacturing-growth narrative.

View full calendar
Times and estimates may change. Verify before trading.